Citi Resumes Buy Rating on Ligand Pharmaceuticals Following Acquisition of XOMA Royalty
Citigroup has resumed coverage of Ligand Pharmaceuticals (LGND) with a 'buy' rating. The firm cited the acquisition of XOMA Royalty as adding late-stage assets and generating steady royalty income.
